130 related articles for article (PubMed ID: 34944673)
1. Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study.
Zhang C; Yu Z; Gao S; Ma M; Gou L; Wang C; Wang L; Li J; Zhong L; Zhou Y; Wang W; Song H
Pediatr Rheumatol Online J; 2023 Oct; 21(1):124. PubMed ID: 37848905
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide Alleviates Apoptosis, Oxidative Damage and Inflammation Induced by Pemphigus Vulgaris IgG in HaCat Cells and Neonatal Mice Through MyD88.
Luan C; Lu Z; Chen J; Chen M; Zhao R; Li X
Drug Des Devel Ther; 2023; 17():2821-2839. PubMed ID: 37719363
[TBL] [Abstract][Full Text] [Related]
3. An update on the management of refractory cutaneous lupus erythematosus.
Verdelli A; Corrà A; Mariotti EB; Aimo C; Ruffo di Calabria V; Volpi W; Quintarelli L; Caproni M
Front Med (Lausanne); 2022; 9():941003. PubMed ID: 36213629
[TBL] [Abstract][Full Text] [Related]
4. The Challenge Arising from New Knowledge about Immune and Inflammatory Skin Diseases: Where We Are Today and Where We Are Going.
Campanati A; Martina E; Offidani A
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625686
[TBL] [Abstract][Full Text] [Related]
5. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.
Maronese CA; Pimentel MA; Li MM; Genovese G; Ortega-Loayza AG; Marzano AV
Am J Clin Dermatol; 2022 Sep; 23(5):615-634. PubMed ID: 35606650
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.
Chasset F; Tounsi T; Cesbron E; Barbaud A; Francès C; Arnaud L
J Am Acad Dermatol; 2018 Feb; 78(2):342-350.e4. PubMed ID: 28989111
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways.
Domingo S; Solé C; Moliné T; Ferrer B; Cortés-Hernández J
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944673
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms.
Domingo S; Solé C; Moliné T; Ferrer B; Ordi-Ros J; Cortés-Hernández J
Dermatology; 2020; 236(5):467-476. PubMed ID: 32659758
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Braunstein I; Goodman NG; Rosenbach M; Okawa J; Shah A; Krathen M; Kovarik CL; Luning Prak E; Werth VP
J Am Acad Dermatol; 2012 Apr; 66(4):571-82. PubMed ID: 21821308
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?
Baret I; De Haes P
J Dermatolog Treat; 2015 Apr; 26(2):173-7. PubMed ID: 24731053
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus.
Walchner M; Meurer M; Plewig G; Messer G
Int J Dermatol; 2000 May; 39(5):383-8. PubMed ID: 10849134
[TBL] [Abstract][Full Text] [Related]
13. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide.
Amare GG; Meharie BG; Belayneh YM
J Oncol Pharm Pract; 2021 Apr; 27(3):673-678. PubMed ID: 33249990
[TBL] [Abstract][Full Text] [Related]
14. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study.
Yu H; Lin L; Zhang Z; Zhang H; Hu H
Signal Transduct Target Ther; 2020 Sep; 5(1):209. PubMed ID: 32958760
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
